EW (Edwards Lifesciences) Beneish M-Score: -2.10 (As of Jun. 24, 2026)


EW Edwards Lifesciences Corp EW
97 GF Score
Price $89.66
GF Value $93.14
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Edwards Lifesciences Beneish M-Score?

Edwards Lifesciences EW +3.12% 97 Beneish M-Score is -2.10 as of Jun. 24, 2026. GuruFocus rates EW with a GF Score™ of 97/100 and a GF Value™ of $93.14 (Fairly Valued). The stock has 5 warning signs investors should review. Among 765 Medical Devices & Instruments companies, Edwards Lifesciences ranks worse than 77.52% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.1 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Edwards Lifesciences's Beneish M-Score or its related term are showing as below:

EW' s Beneish M-Score Range Over the Past 10 Years
Min: -3.01   Med: -2.26   Max: -1.15
Current: -2.1

During the past 13 years, the highest Beneish M-Score of Edwards Lifesciences was -1.15. The lowest was -3.01. And the median was -2.26.


Edwards Lifesciences Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Edwards Lifesciences's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Edwards Lifesciences Beneish M-Score Chart

Edwards Lifesciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.49 -2.28 -1.98 -1.24 -2.30

Edwards Lifesciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.36 -1.15 -2.10 -2.30 -2.10

EW vs DXCM, GEHC, BSX: Beneish M-Score Comparison

For the Medical Devices subindustry, Edwards Lifesciences's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Edwards Lifesciences Beneish M-Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Edwards Lifesciences's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Edwards Lifesciences's Beneish M-Score falls into.


EW
97GF Score
Edwards Lifesciences Corp EW
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Edwards Lifesciences Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Edwards Lifesciences for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.1337+0.528 * 1.021+0.404 * 1.0079+0.892 * 1.1415+0.115 * 1.0187
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.0273+4.679 * 0.024217-0.327 * 0.9856
=-2.10

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was $973 Mil.
Revenue was 1648.6 + 1569.6 + 1553.1 + 1532.2 = $6,304 Mil.
Gross Profit was 1286 + 1226.6 + 1207.9 + 1187.8 = $4,908 Mil.
Total Current Assets was $6,229 Mil.
Total Assets was $13,321 Mil.
Property, Plant and Equipment(Net PPE) was $1,922 Mil.
Depreciation, Depletion and Amortization(DDA) was $161 Mil.
Selling, General, & Admin. Expense(SGA) was $2,142 Mil.
Total Current Liabilities was $1,409 Mil.
Long-Term Debt & Capital Lease Obligation was $679 Mil.
Net Income was 380.7 + 91.2 + 291.1 + 329.8 = $1,093 Mil.
Non Operating Income was -89.2 + -315.8 + -115.3 + -68.1 = $-588 Mil.
Cash Flow from Operations was 43.8 + 450.9 + 573.7 + 290.2 = $1,359 Mil.
Total Receivables was $752 Mil.
Revenue was 1412.7 + 1385.8 + 1354.4 + 1369.4 = $5,522 Mil.
Gross Profit was 1111.1 + 1093.6 + 1091.5 + 1093.9 = $4,390 Mil.
Total Current Assets was $6,213 Mil.
Total Assets was $13,022 Mil.
Property, Plant and Equipment(Net PPE) was $1,795 Mil.
Depreciation, Depletion and Amortization(DDA) was $153 Mil.
Selling, General, & Admin. Expense(SGA) was $1,827 Mil.
Total Current Liabilities was $1,395 Mil.
Long-Term Debt & Capital Lease Obligation was $676 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(973 / 6303.5) / (751.9 / 5522.3)
=0.154359 / 0.136157
=1.1337

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(4390.1 / 5522.3) / (4908.3 / 6303.5)
=0.794977 / 0.778663
=1.021

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (6228.7 + 1922.4) / 13321.2) / (1 - (6212.7 + 1795.2) / 13022.3)
=0.388111 / 0.385063
=1.0079

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=6303.5 / 5522.3
=1.1415

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(153.3 / (153.3 + 1795.2)) / (160.9 / (160.9 + 1922.4))
=0.078676 / 0.077233
=1.0187

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(2141.7 / 6303.5) / (1826.5 / 5522.3)
=0.339764 / 0.33075
=1.0273

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((678.6 + 1409) / 13321.2) / ((675.7 + 1394.8) / 13022.3)
=0.156713 / 0.158996
=0.9856

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(1092.8 - -588.4 - 1358.6) / 13321.2
=0.024217

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Edwards Lifesciences has a M-score of -2.10 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.10 mean?
Edwards Lifesciences (EW) has a Beneish M-Score of -2.10 as of Jun. 24, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Edwards Lifesciences and its competitors. According to the industry distribution chart, Edwards Lifesciences ranks #593 out of 765 companies in the Medical Devices & Instruments industry, placing it in the top 77.5%.
Is Edwards Lifesciences' Beneish M-Score too high?
Edwards Lifesciences' current Beneish M-Score is -2.10. Based on the distribution chart, Edwards Lifesciences ranks #593 out of 765 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Edwards Lifesciences has a GF Score™ of 97/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Edwards Lifesciences' Beneish M-Score compare to DXCM and GEHC?
According to the Medical Devices & Instruments industry distribution chart, Edwards Lifesciences ranks #593 out of 765 companies for Beneish M-Score. This places Edwards Lifesciences in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Medical Devices & Instruments company?
A good Beneish M-Score depends on the Medical Devices & Instruments industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Edwards Lifesciences and its competitors. Edwards Lifesciences's current Beneish M-Score is -2.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Edwards Lifesciences stock overvalued right now?
Based on GuruFocus' analysis, Edwards Lifesciences (EW) is currently considered Fairly Valued. The stock's GF Value™ is $93.14, compared to a current price of $89.66 — trading 3.7% below its estimated fair value. The current Beneish M-Score is -2.10. Edwards Lifesciences' overall GF Score™ is 97/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Edwards Lifesciences (EW), the current Beneish M-Score is -2.10 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Edwards Lifesciences (EW) Overvalued in 2026?

Based on GuruFocus' analysis, Edwards Lifesciences stock appears to be undervalued. The current stock price of $89.66 is trading 3.7% below its estimated GF Value™ of $93.14. GuruFocus considers Edwards Lifesciences to be Fairly Valued.

Key valuation signals for EW:

  • Beneish M-Score: -2.10
  • GF Value™: $93.14 vs. price of $89.66 (3.7% below fair value)
  • GF Score™: 97/100 with 5 warning signs

No single metric tells the full story. See the EW stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Edwards Lifesciences Business Description

Address One Edwards Way, Irvine, CA, USA, 92614
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.
97GF Score

Get the complete analysis for EW

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$89.66
Price
$93.14
GF Value